Results 21 to 30 of about 21,080,479 (286)
Advances in Universal CAR-T Cell Therapy
Frontiers in Immunology, 2021 Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements results in antitumor treatments, especially against hematological malignancies, where it leads to remarkable, long-term antineoplastic effects with higher target ...
Haolong Lin +4 more
doaj +1 more source
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
Current Issues in Molecular Biology, 2023 Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte.
Hong Yun Ma +11 more
doaj +1 more source
CAR-T Cell Therapy and the Gut Microbiota
, 2023 Chimeric antigen receptor (CAR) - T cell cancer therapy has yielded promising results in treating hematologic malignancies in clinical studies, and a growing number of CAR-T regimens are approved for clinical usage.
Nyssa Cullin +7 more
core +1 more source
Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy. [PDF]
, 2023 Chimeric antigen receptor (CAR)-T cell therapy is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) with response rates of 63-84% and complete response observed in 43-54%.
Mariesol Abbühl +11 more
core +2 more sources
CAR T-cell therapy and critical care : A survival guide for medical emergency teams. [PDF]
, 2021 Chimeric antigen receptor (CAR) T‑cells are genetically engineered to give T‑cells the ability to attack specific cancer cells, and to improve outcome of patients with refractory/relapsed aggressive B‑cell malignancies.
Que, Yok-Ai +13 more
core +2 more sources
Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
Frontiers in Immunology, 2022 The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies.
Feifei Nan +9 more
doaj +1 more source
CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth
, 2023 New therapies in a publicly funded healthcare system are first appraised by health technology assessment agencies that provide funding recommendations to the payers.
Pierre J. A. Villeneuve +1 more
core +1 more source
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement. [PDF]
, 2023 Efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement remain understudied.
Urban Novak +17 more
core +2 more sources
CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead
Journal of Immunology Research, 2020 Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. Like other technologies, CAR-T cell therapy has undergone a long development process, and persistent explorations of the ...
Qingyang Zhang +7 more
doaj +1 more source
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited.
Van To +11 more
doaj +1 more source